Table 4 Logistic regression results for the associations of TDP-43 positivity with the clinical, demographic and biological characteristics of patients with MND
From: TDP-43 seeding activity in the olfactory mucosa of patients with amyotrophic lateral sclerosis
Clinical parameter | Group | TDP-43_SAA result | Univariate OR (95% CI, p value) | |
|---|---|---|---|---|
Negative | Positive | |||
Sex | Female | 18 (64.3%) | 10 (35.7%) | ref |
Male | 30 (51.7%) | 28 (48.3%) | 1.680 (0.672–4.367, p = 0.2737) | |
Age, years | Mean (SD) | 61.0 (10.3) | 63.1 (9.8) | 1.021 (0.979–1.068, p = 0.3357) |
BMI, kg/m2 | Mean (SD) | 23.9 (3.4) | 24.8 (3.9) | 1.077 (0.952–1.228, p = 0.2470) |
Genotype | Genetic | 12 (57.1%) | 9 (42.9%) | ref |
Sporadic | 36 (55.4%) | 29 (44.6%) | 1.074 (0.399–2.965, p = 0.8878) | |
Clinical phenotype* | sALS | 29 (60.4%) | 19 (39.6%) | ref |
bALS | 14 (58.3%) | 10 (41.7%) | 1.090 (0.396–2.950, p = 0.8651) | |
PLS | 4 (36.4%) | 7 (63.6%) | 2.671 (0.708–11.391, p = 0.1562) | |
FOSMN | 1 (50.0%) | 1 (50.0%) | 1.526 (0.058–40.182, p = 0.7698) | |
Cognitive phenotype | Normal | 25 (55.6%) | 20 (44.4%) | ref |
Impaired | 17 (56.7%) | 13 (43.3%) | 0.956 (0.373–2.427, p = 0.9243) | |
ECAS, ALS-specific | Mean (SD) | 68.8 (11.8) | 69.3 (13.6) | 1.003 (0.965–1.044, p = 0.8703) |
ECAS, non-ALS specific | Mean (SD) | 26.0 (4.5) | 25.4 (4.3) | 0.970 (0.867–1.082, p = 0.5826) |
ECAS, total | Mean (SD) | 94.7 (14.5) | 94.6 (16.1) | 1.000 (0.968–1.033, p = 0.9822) |
Disease duration, months | Mean (SD) | 29.9 (29.1) | 35.2 (32.5) | 1.006 (0.991–1.021, p = 0.4326) |
King’s clinical staging | 1 | 7 (53.8%) | 6 (46.2%) | ref |
2 | 20 (69.0%) | 9 (31.0%) | 0.525 (0.134–2.046, p = 0.3476) | |
3 | 12 (60.0%) | 8 (40.0%) | 0.778 (0.186–3.239, p = 0.7269) | |
4a | 2 (66.7%) | 1 (33.3%) | 0.583 (0.024–7.681, p = 0.6887) | |
4b | 2 (33.3%) | 4 (66.7%) | 2.333 (0.328–21.558, p = 0.4104) | |
ΔFS | Mean (SD) | 0.6 (0.7) | 0.6 (0.6) | 1.031 (0.458–2.215, p = 0.9358) |
Rate of progression | Slow | 26 (61.9%) | 16 (38.1%) | ref |
Intermediate | 9 (60.0%) | 6 (40.0%) | 1.083 (0.312–3.595, p = 0.8965) | |
Fast | 7 (53.8%) | 6 (46.2%) | 1.393 (0.386–4.941, p = 0.6050) | |
Riluzole treatment | Absent | 32 (54.2%) | 27 (45.8%) | ref |
Present | 16 (59.3%) | 11 (40.7%) | 0.815 (0.318–2.039, p = 0.6636) | |
TDP-43 Simoa, pg/ml | Mean (SD) | 3 958.2 (2 472.2) | 3 565.8 (2 098.5) | 1.000 (1.000–1.000, p = 0.5360) |
NfL Lumipulse | Mean (SD) | 79.9 (66.8) | 87.0 (72.8) | 1.002 (0.993–1.010, p = 0.7067) |